ABSTRACT
PURPOSE: The simultaneous occurrence of cerebral toxoplasmosis and cryptococcosis is rare. The infections continue to be treated with sulfadiazine and amphotericin-B-based regimens (preferred therapy), respectively. Both these drugs are linked to some serious adverse drug reactions (ADRs). We report such a unique instance of both; the CNS co-infections and adverse drug reactions to the preferred therapy. CASE PRESENTATION: A 44-year-old Asian-Indian female was diagnosed with cerebral toxoplasmosis, impending cryptococcal meningoencephalitis, and acquired immune deficiency syndrome (AIDS). The preferred therapy of opportunistic CNS co-infections commenced. Within a week, she had an occurrence of fall in hemoglobin concentrations (11.3 g/dL to 5.6 g/dL; grade IV), reticulocytosis (1% to 3.2%), and indirect hyperbilirubinemia (0.5 mg/dL to 2.8 mg/dL; grade IV) after sulfadiazine administration. The drug was discontinued and the patient was treated with hematocrit transfusions. After amphotericin-B deoxycholate (AmBd) administration, the patient developed hypokalemia (serum potassium; 4.5 mmol/L to 2.7 mmol/L) and increased serum creatinine (1.0 to 2.2 mg/dL; stage-I) levels. Hence, AmBd was discontinued and potassium correction was given. The patient got diagnosed with sulfadiazine induced hemolytic anemia and AmBd induced acute renal failure. He was switched to alternative therapy regimens for the treatment of cerebral toxoplasmosis and cryptococcosis. Radiological investigations were followed up to confirm the clinical outcomes of alternative therapy. Complete recovery from the ADRs and opportunistic infections was observed. CONCLUSION: The preferred therapy regimens for toxoplasmosis and cryptococcosis are accompanied by potential adverse drug reactions, thus continuous monitoring is vital, especially in the initial phases of therapy. Discontinuation of the treatment should be the preliminary intervention in the management. Having said that, alternative therapy regimens had an optimal clinical response in the present case.
Subject(s)
Acquired Immunodeficiency Syndrome , Coinfection , Cryptococcosis , Drug-Related Side Effects and Adverse Reactions , Toxoplasmosis, Cerebral , Male , Humans , Female , Adult , Amphotericin B/adverse effects , Acquired Immunodeficiency Syndrome/chemically induced , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Antifungal Agents/adverse effects , Toxoplasmosis, Cerebral/diagnosis , Toxoplasmosis, Cerebral/drug therapy , Toxoplasmosis, Cerebral/chemically induced , Coinfection/chemically induced , Coinfection/complications , Coinfection/drug therapy , Cryptococcosis/complications , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Sulfadiazine/adverse effects , Potassium/therapeutic useABSTRACT
BACKGROUND: Although the price increase of pyrimethamine in 2015 received heavy media coverage, there are little data regarding specific implications to hospitals and the total costs of treating inpatients with toxoplasmosis encephalitis (TE). METHODS: Using average drug wholesale costs, we estimated the inpatient drug costs of TE drugs 3 years prepyrimethamine and postpyrimethamine price increase in August 2015. The drug regimens and total doses were determined through retrospective chart review of patients living with HIV who received treatment for TE while inpatient during this period. RESULTS: The 3-year pre-increase TE drug costs for 66 admissions were estimated at $50,310 compared with a total drug cost of $1,026,006 for 61 admissions postincrease. Pyrimethamine made up 98% of the drug costs postincrease, compared with 57% pre-increase. Pyrimethamine-based regimens were the most frequently used throughout the study period. CONCLUSIONS: The price increase of pyrimethamine in 2015 led to a substantial and unnecessary financial burden to hospitals. This required health care systems to shift valuable resources to continue to provide medications to a vulnerable patient population. There has been more focus on providing high-value care in recent years. Our study highlights the need for further examination of pharmaceutical companies' arbitrary determination of medication costs and how they contribute to patient care.
Subject(s)
Encephalitis , HIV Infections , Toxoplasmosis, Cerebral , Financial Stress , HIV Infections/drug therapy , Humans , Pharmaceutical Preparations , Pyrimethamine/therapeutic use , Retrospective Studies , Safety-net Providers , Toxoplasmosis, Cerebral/chemically induced , Toxoplasmosis, Cerebral/drug therapySubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematologic Neoplasms/drug therapy , Toxoplasma/isolation & purification , Toxoplasmosis, Cerebral/diagnosis , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bendamustine Hydrochloride/administration & dosage , Bendamustine Hydrochloride/adverse effects , Diagnosis, Differential , Female , Hematologic Neoplasms/diagnosis , Humans , Rituximab/administration & dosage , Rituximab/adverse effects , Toxoplasma/physiology , Toxoplasmosis, Cerebral/chemically induced , Toxoplasmosis, Cerebral/parasitologySubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Toxoplasmosis, Cerebral/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antirheumatic Agents/therapeutic use , Biopsy , Brain/parasitology , Brain/pathology , Humans , Male , Risk Factors , Toxoplasma/isolation & purification , Toxoplasmosis, Cerebral/chemically induced , Toxoplasmosis, Cerebral/diagnosisSubject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Toxoplasmosis/diagnosis , Adult , Choroiditis/etiology , Choroiditis/pathology , Choroiditis/therapy , Diagnostic Imaging , Hematopoietic Stem Cell Transplantation/methods , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Male , Retinal Diseases/chemically induced , Retinal Diseases/diagnosis , Toxoplasmosis/chemically induced , Toxoplasmosis, Cerebral/chemically induced , Toxoplasmosis, Cerebral/diagnosisABSTRACT
HIV therapy has advanced greatly in the past couple of decades. Along with advances in treatment have come new adverse effects associated with therapy. We present a case of Toxoplasma encephalitis following initiation of HAART consistent with the emerging syndrome known as immune restoration disease.